JP2012520081A - Sparc血管新生ドメイン及び使用方法 - Google Patents

Sparc血管新生ドメイン及び使用方法 Download PDF

Info

Publication number
JP2012520081A
JP2012520081A JP2011554211A JP2011554211A JP2012520081A JP 2012520081 A JP2012520081 A JP 2012520081A JP 2011554211 A JP2011554211 A JP 2011554211A JP 2011554211 A JP2011554211 A JP 2011554211A JP 2012520081 A JP2012520081 A JP 2012520081A
Authority
JP
Japan
Prior art keywords
tumor
seq
sparc
polypeptide
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011554211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520081A5 (cg-RX-API-DMAC7.html
Inventor
チェウ、ヴォン
ナウアー、ダニエル
デサイ、ニール
Original Assignee
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー filed Critical アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー
Publication of JP2012520081A publication Critical patent/JP2012520081A/ja
Publication of JP2012520081A5 publication Critical patent/JP2012520081A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011554211A 2009-03-11 2010-03-11 Sparc血管新生ドメイン及び使用方法 Pending JP2012520081A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15932209P 2009-03-11 2009-03-11
US61/159,322 2009-03-11
PCT/US2010/027041 WO2010105097A2 (en) 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use

Publications (2)

Publication Number Publication Date
JP2012520081A true JP2012520081A (ja) 2012-09-06
JP2012520081A5 JP2012520081A5 (cg-RX-API-DMAC7.html) 2013-05-02

Family

ID=42729116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554211A Pending JP2012520081A (ja) 2009-03-11 2010-03-11 Sparc血管新生ドメイン及び使用方法

Country Status (13)

Country Link
US (2) US20120087910A1 (cg-RX-API-DMAC7.html)
EP (1) EP2405932A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012520081A (cg-RX-API-DMAC7.html)
KR (2) KR20130043242A (cg-RX-API-DMAC7.html)
CN (2) CN102482334A (cg-RX-API-DMAC7.html)
AU (1) AU2010224031B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1009457A2 (cg-RX-API-DMAC7.html)
CA (1) CA2755109A1 (cg-RX-API-DMAC7.html)
IL (2) IL215089A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011009478A (cg-RX-API-DMAC7.html)
NZ (1) NZ595528A (cg-RX-API-DMAC7.html)
WO (1) WO2010105097A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107415B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544704A4 (en) * 2010-03-11 2013-08-28 Abraxis Bioscience Llc SPARC ANGIOGENIC DOMAIN AND METHODS OF USE
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN120361186B (zh) * 2025-04-15 2025-12-30 北京大学口腔医学院 一种促进血管生成和组织再生的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
WO2008000079A1 (en) * 2006-06-26 2008-01-03 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
CN101678078B (zh) * 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014032394; KUAUER D et al: 'Identification of the albumin-binding domain and the angiogenic domen of SPARC' European Journal of Cancer supplement, vol.7, no.2, 20090901, p.87-88 *
JPN6014032397; KNAUER D. et al: 'Albumin-Binding and Angiogenic Domains of SPARC Located at Its C-Terminus' Cancer Research 69, 24, supplement 3, 20091215 *
JPN6014032400; JENDRASCHAK E. et al: 'Regulations of angiogenesis by SPARC and angiostatin: implications for tumor cell biology' seminars in CANCER BIOLOGY 7, 1996, p.139-146 *

Also Published As

Publication number Publication date
EP2405932A2 (en) 2012-01-18
US20120087910A1 (en) 2012-04-12
MX2011009478A (es) 2011-11-18
IL215089A0 (en) 2011-11-30
CN103724417A (zh) 2014-04-16
CA2755109A1 (en) 2010-09-16
WO2010105097A3 (en) 2010-11-04
US20140094416A1 (en) 2014-04-03
KR20130043242A (ko) 2013-04-29
BRPI1009457A2 (pt) 2016-03-01
WO2010105097A8 (en) 2011-05-26
KR20110139256A (ko) 2011-12-28
AU2010224031B2 (en) 2013-05-02
AU2010224031A1 (en) 2011-10-06
ZA201107415B (en) 2012-06-27
AU2010224031A2 (en) 2011-10-20
WO2010105097A2 (en) 2010-09-16
EP2405932A4 (en) 2012-08-22
CN102482334A (zh) 2012-05-30
NZ595528A (en) 2013-10-25
IL228795A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
JP5622885B2 (ja) 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
AU2003216288B2 (en) Modulation of immune response by non-peptide binding stress response polypeptides
US20140094416A1 (en) Sparc angiogenic domain and methods of use
JP2014144014A (ja) 化学療法増感剤としてのシステインに富む酸性分泌タンパク質(sparc)
CA2945812A1 (en) Trail receptor agonists for treatment of fibrotic diseases
JP2020531409A (ja) ホスファチジルセリン標的化融合分子およびそれらの使用方法
CA3019999A1 (en) Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumoral immunity
EP2630963A1 (en) SPARC angiogenic domain and methods of use
AU2013211470A1 (en) Sparc angiogenic domain and methods of use
HK1194403A (en) Sparc angiogenic domain and methods of use
HK1167664A (en) Sparc angiogenic domain and methods of use
US11208468B2 (en) Methods and compositions for treating melanoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150113